Beijing Hotgen Biotech Co Ltd
SSE:688068
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Beijing Hotgen Biotech Co Ltd
Other Liabilities
Beijing Hotgen Biotech Co Ltd
Other Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Beijing Hotgen Biotech Co Ltd
SSE:688068
|
Other Liabilities
¥13.9m
|
CAGR 3-Years
8%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
WuXi AppTec Co Ltd
SSE:603259
|
Other Liabilities
¥948.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
|
|
Pharmaron Beijing Co Ltd
SZSE:300759
|
Other Liabilities
¥442.9m
|
CAGR 3-Years
19%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
WuXi Biologics (Cayman) Inc
HKEX:2269
|
Other Liabilities
¥362.2m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
|
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
|
Other Liabilities
¥27.3m
|
CAGR 3-Years
-32%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-4%
|
|
|
W
|
WuXi XDC Cayman Inc
HKEX:2268
|
Other Liabilities
¥11.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Beijing Hotgen Biotech Co Ltd
Glance View
Beijing Hotgen Biotech Co., Ltd. engages in the development and manufacturing of in-vitro diagnostic, point-of-care-testing, and biodefense products. The company is headquartered in Beijing, Beijing and currently employs 1,019 full-time employees. The company went IPO on 2019-09-30. The firm's products mainly include in vitro diagnostic reagents, in vitro diagnostic instruments and biological raw materials. Its products are mainly used in clinical fields such as liver cancer, hepatitis, cardiovascular and cerebrovascular diseases, and inflammatory infections, as well as in public safety and other fields such as biosafety, food safety, and disease control and emergency response. The firm primarily conducts its businesses in domestic and overseas markets.
See Also
What is Beijing Hotgen Biotech Co Ltd's Other Liabilities?
Other Liabilities
13.9m
CNY
Based on the financial report for Sep 30, 2025, Beijing Hotgen Biotech Co Ltd's Other Liabilities amounts to 13.9m CNY.
What is Beijing Hotgen Biotech Co Ltd's Other Liabilities growth rate?
Other Liabilities CAGR 5Y
10%
Over the last year, the Other Liabilities growth was -1%. The average annual Other Liabilities growth rates for Beijing Hotgen Biotech Co Ltd have been 8% over the past three years , 10% over the past five years .
